Real-Life Efficacy and Safety of Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir in Chronic Hepatitis C Patients in Hong Kong.

Background and Aim In registration studies, combination therapy of paritaprevir/ritonavir, ombitasvir and dasabuvir (PrOD) with and without ribavirin for 12-24 weeks can achieve >90% sustained virological response (SVR) for genotype 1 hepatitis C virus (HCV) infection. However, data in Asia is scanty. We aimed to study the efficacy and safety of this combination therapy in chronic hepatitis C patients in Hong Kong. Methods We retrospectively analyzed data from 6 local hospitals which have prescribed PrOD with and without ribavirin to patients with genotype 1 chronic HCV infection as part of a global compassionate program. Results Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection; 6 (15%) had co-infection with HIV; 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis and 3 (7%) had liver transplantation. Thirty-five (85%) patients received 12 weeks and 6 patients received 24 weeks treatment; 26 (63%) patients received ribavirin combination. Thirty-nine (95%; 95% confidence interval 88.5%-100%) patients had undetectable HCV RNA at 12 weeks post-treatment, i.e. SVR. The 2 patients who did not develop SVR discontinued treatment prematurely; both of them were treatment experienced with liver cirrhosis complicated by acute renal failure unrelated to the treatment of PrOD and ribavirin. No patient had hepatic decompensation. Conclusions PrOD with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real-life clinical setting in Hong Kong.